While the CD133/AC133+ PSC population may acquire oncogenic mutations, its differentiated (CD133/AC133−) progeny may subsequently undergo oncogenic transformation and correspond to the PCa cell-of-origin. This evidence concerns the gene PROM1 and posterior cortical atrophy.